TG Therapeutics Completes Enrollment in Phase 3 Trial for Subcutaneous BRIUMVI
Event summary
- TG Therapeutics completed enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI for relapsing multiple sclerosis (RMS).
- The trial compares two subcutaneous dosing regimens (every 2 months or every 3 months) against the approved intravenous (IV) formulation.
- Top-line data from the trial is expected by year-end 2026 or early 2027.
- BRIUMVI is currently approved in the U.S. and several ex-U.S. territories for RMS.
The big picture
The completion of enrollment in this Phase 3 trial marks a significant step in TG Therapeutics' efforts to expand the BRIUMVI franchise. The shift to a subcutaneous formulation could broaden the drug's reach by offering patients greater flexibility and convenience, potentially increasing market penetration. This development comes amid a competitive landscape in the RMS treatment space, where convenience and patient adherence are increasingly important differentiators.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 trial results will support regulatory approval for the subcutaneous formulation of BRIUMVI.
- Market Adoption
- The pace at which patients and healthcare providers will adopt the subcutaneous version if approved, given its potential for at-home administration.
- Competitive Positioning
- How TG Therapeutics will position subcutaneous BRIUMVI against existing RMS treatments, particularly those with similar convenience features.
Related topics